<DOC>
	<DOCNO>NCT00693966</DOCNO>
	<brief_summary>The purpose Phase II study provide data regard safety immunogenicity range dose level MEDI-517 woman HPV-16/18 seronegative negative high-risk HPV DNA . The study design evaluate safety immunogenicity data MEDI-517 formulate either AS04 aluminum hydroxide . Extended follow-up provide long-term immune response data . This study originally perform MedImmune . However , GSK responsible clinical development HPV vaccine .</brief_summary>
	<brief_title>Dose-Comparison Study Evaluate Safety Immunogenicity MEDI-517 ( GSK 580299 ) Healthy Adult Females</brief_title>
	<detailed_description>This Phase II double-blind , randomize , dose-comparison , multicenter study United States three different dose level MEDI-517 ( HPV-16/18 VLP AS04 vaccine ) one dose MEDI-517 formulate aluminum hydroxide , dose administered 0 , 30 180 day . Healthy female volunteer 18 30 year age enter 4 treatment arm . The objective study evaluate reactogenicity , safety immunogenicity .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Females 18 30 year age ( must reach 31st birthday ) Unless previously surgically sterilize , agree use effective method birth control begin 30 day first study injection continue 60 day final study injection Healthy medical history physical examination Seronegative HPV16 HPV18 antibody ELISA within 21 day study entry Cervical specimen negative highrisk HPV DNA use Digene Hybrid Capture® II HPV test ( highrisk type Probe B ) within 21 day study entry Normal Pap smear , use Cytyc ThinPrep® Pap Test , within 21 day study entry No evidence anogenital HPV lesion physical finding suggestive gynecologic pathogen pelvic examination within 21 day study entry Agrees experimental therapy vaccine 30 day last study injection Written inform consent obtain volunteer Acute illness fever ( oral temperature ≥ 99.5°F [ 37.5°C ] ) start study History clinical manifestation significant medical psychiatric disorder Pregnant lactating Use immunosuppressive medication within previous 90 day history immunodeficiency History cancer History alcohol drug abuse within past 2 year Abnormal laboratory value screen panel opinion principal investigator judge clinically significant Receipt immunoglobulin blood product within 90 day prior study entry History abnormal Pap smear ( single prior report ASCUS indeterminate Pap smear subsequent normal report ) Positive test hepatitis C antibody , hepatitis B surface antigen , HIV1 antibody Any prior receipt vaccine ( experimental otherwise ) treatment prophylaxis genital wart papillomavirus relate condition . Any treatment genital wart papillomavirus relate condition within 6 month randomization ( local therapy common skin and/or plantar wart allow ) Previous administration component investigational vaccine Receipt experimental vaccine within 90 day prior entry study Receipt experimental drug therapy within 30 day five halflives experimental drug ( halflife know ) , whichever long</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HPV , Vaccine</keyword>
</DOC>